Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

fadraciclib (CYC065)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cyclacel

Drug class:

CDK9 inhibitor, CDK2 inhibitor

Related drugs:

MCL1 amplification	Endometrial Cancer	MCL1 amplification	Endometrial Cancer	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3
CD133 positive	Glioblastoma	CD133 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
CD44 positive	Glioblastoma	CD44 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D
BRCA1 2080delA	Breast Cancer	BRCA1 2080delA	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D
BRCA1 R1443*	Breast Cancer	BRCA1 R1443*	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D